Joon Lee
Stock Analyst at Truist Financial
(4.97)
# 84
Out of 4,516 analysts
549
Total ratings
59.4%
Success rate
37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joon Lee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VYGR Voyager Therapeutics | Maintained: Buy | n/a | $3.20 | - | 16 | Mar 17, 2026 | |
| EDIT Editas Medicine | Maintained: Hold | n/a | $3.04 | - | 22 | Mar 17, 2026 | |
| SLDB Solid Biosciences | Maintained: Buy | n/a | $9.62 | - | 11 | Mar 13, 2026 | |
| PRAX Praxis Precision Medicines | Reiterated: Buy | $700 | $318.42 | +119.84% | 29 | Mar 12, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintained: Buy | $525 | $477.08 | +10.04% | 16 | Mar 11, 2026 | |
| ANAB AnaptysBio | Maintained: Hold | $50 | $55.82 | -10.43% | 30 | Mar 9, 2026 | |
| VKTX Viking Therapeutics | Maintained: Buy | n/a | $37.81 | - | 43 | Mar 5, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintained: Buy | n/a | $58.95 | - | 14 | Mar 3, 2026 | |
| CORT Corcept Therapeutics | Maintained: Buy | n/a | $89.57 | - | 38 | Mar 2, 2026 | |
| NTLA Intellia Therapeutics | Maintained: Buy | n/a | $13.04 | - | 29 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $51.37 | - | 24 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $78.84 | - | 11 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $5.91 | - | 41 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $51.98 | - | 3 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $31.49 | - | 31 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $239.32 | - | 26 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $237.53 | - | 37 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $90 → $76 | $31.71 | +139.67% | 29 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $39.93 | - | 2 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $3.81 | - | 8 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $6.19 | - | 24 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $862.93 | - | 38 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $11.03 | n/a | 1 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $8.42 | n/a | 10 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $100 → $65 | $8.28 | n/a | 5 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $7 → $4 | $6.21 | n/a | 4 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $3.71 | n/a | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $12.59 | n/a | 1 | Aug 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $76 | $41.00 | n/a | 1 | Jun 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $7.29 | n/a | 1 | Jun 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $17.61 | n/a | 1 | Aug 8, 2014 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $33 | $25.92 | n/a | 1 | Aug 7, 2014 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 | $1.44 | n/a | 1 | Jul 28, 2014 |
Voyager Therapeutics
Mar 17, 2026
Maintained: Buy
Price Target: n/a
Current: $3.20
Upside: -
Editas Medicine
Mar 17, 2026
Maintained: Hold
Price Target: n/a
Current: $3.04
Upside: -
Solid Biosciences
Mar 13, 2026
Maintained: Buy
Price Target: n/a
Current: $9.62
Upside: -
Praxis Precision Medicines
Mar 12, 2026
Reiterated: Buy
Price Target: $700
Current: $318.42
Upside: +119.84%
Vertex Pharmaceuticals
Mar 11, 2026
Maintained: Buy
Price Target: $525
Current: $477.08
Upside: +10.04%
AnaptysBio
Mar 9, 2026
Maintained: Hold
Price Target: $50
Current: $55.82
Upside: -10.43%
Viking Therapeutics
Mar 5, 2026
Maintained: Buy
Price Target: n/a
Current: $37.81
Upside: -
BioMarin Pharmaceutical
Mar 3, 2026
Maintained: Buy
Price Target: n/a
Current: $58.95
Upside: -
Corcept Therapeutics
Mar 2, 2026
Maintained: Buy
Price Target: n/a
Current: $89.57
Upside: -
Intellia Therapeutics
Mar 2, 2026
Maintained: Buy
Price Target: n/a
Current: $13.04
Upside: -
Mar 2, 2026
Maintained: Buy
Price Target: n/a
Current: $51.37
Upside: -
Feb 27, 2026
Maintained: Buy
Price Target: n/a
Current: $78.84
Upside: -
Feb 27, 2026
Reiterated: Buy
Price Target: n/a
Current: $5.91
Upside: -
Feb 26, 2026
Maintained: Buy
Price Target: n/a
Current: $51.98
Upside: -
Feb 26, 2026
Maintained: Buy
Price Target: n/a
Current: $31.49
Upside: -
Feb 25, 2026
Maintained: Buy
Price Target: n/a
Current: $239.32
Upside: -
Feb 24, 2026
Maintained: Buy
Price Target: n/a
Current: $237.53
Upside: -
Feb 13, 2026
Maintained: Buy
Price Target: $90 → $76
Current: $31.71
Upside: +139.67%
Nov 10, 2025
Maintained: Buy
Price Target: n/a
Current: $39.93
Upside: -
Nov 6, 2025
Maintained: Buy
Price Target: n/a
Current: $3.81
Upside: -
Nov 5, 2025
Maintained: Buy
Price Target: n/a
Current: $6.19
Upside: -
Aug 1, 2025
Maintained: Buy
Price Target: n/a
Current: $862.93
Upside: -
Dec 4, 2024
Rated: Buy
Price Target: n/a
Current: $11.03
Upside: n/a
Nov 14, 2023
Maintained: Buy
Price Target: $18
Current: $8.42
Upside: n/a
Jan 17, 2023
Maintained: Buy
Price Target: $100 → $65
Current: $8.28
Upside: n/a
Dec 8, 2022
Maintained: Hold
Price Target: $7 → $4
Current: $6.21
Upside: n/a
May 5, 2022
Reiterated: Buy
Price Target: $14
Current: $3.71
Upside: n/a
Aug 8, 2019
Maintained: Buy
Price Target: $10
Current: $12.59
Upside: n/a
Jun 19, 2019
Initiated Coverage: Buy
Price Target: $76
Current: $41.00
Upside: n/a
Jun 19, 2019
Initiated Coverage: Buy
Price Target: $20
Current: $7.29
Upside: n/a
Aug 8, 2014
Maintained: Buy
Price Target: n/a
Current: $17.61
Upside: n/a
Aug 7, 2014
Reiterated: Buy
Price Target: $33
Current: $25.92
Upside: n/a
Jul 28, 2014
Maintained: Buy
Price Target: $14
Current: $1.44
Upside: n/a